Bin Qing Xiao
Direktor/Vorstandsmitglied bei GEMPHARMATECH CO., LTD.
Ursprung des Netzwerks ersten Grades von Bin Qing Xiao
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Biotechnology | 17 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Bin Qing Xiao
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| Nanjing University | College/University | Graduate Degree Doctorate Degree Undergraduate Degree Doctorate Degree | |
| Yale University | College/University | Graduate Degree Doctorate Degree | |
| MICRO-TECH (NANJING) CO.,LTD | Medical Specialties | Founder | |
| AVIT LTD. | Telecommunications Equipment | Director/Board Member | |
Genfleet Therapeutics (Shanghai), Inc.
 Genfleet Therapeutics (Shanghai), Inc. Miscellaneous Commercial ServicesCommercial Services Genfleet Therapeutics (Shanghai), Inc. is a Chinese clinical-stage biotechnology company that focuses on developing novel drug candidates for unmet medical needs in oncology and immunology. The company is based in Shanghai, China, and was founded in 2017 by Jiong Lan and Qiang Lü. The company has built up industry-leading capabilities and expertise in developing both small molecules and biologics since its inception in 2017. Genfleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and IP. The company's pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China. Genfleet has completed co-development partnerships with a number of publicly listed companies worldwide. Jiong Lan has been the CEO since 2017. | Miscellaneous Commercial Services | Director/Board Member | |
Innolake Pharmaceuticals (Hangzhou) Co., Ltd.
 Innolake Pharmaceuticals (Hangzhou) Co., Ltd. Pharmaceuticals: MajorHealth Technology Innolake Pharmaceuticals (Hangzhou) Co., Ltd. is a company based in Hangzhou, China that engages in the development and commercialization of therapeutic drugs for tumors and immune system diseases. The Chinese company was founded in 2020 by Ru Lei Chen and Ming De Xia, with Ming De Xia serving as the CEO since 2020. | Pharmaceuticals: Major | Director/Board Member | |
| Nanyang Technological University | College/University | Graduate Degree | |
Suzhou Xiangyuan New Materials Co., Ltd.
 Suzhou Xiangyuan New Materials Co., Ltd. Chemicals: SpecialtyProcess Industries Suzhou Xiangyuan New Materials Co., Ltd. principally engages in the research, development, production, and sale of polyurethane chain extenders. Its key products are fine chemical products and new polyurethane chain extenders. The company was founded by Jian Zhou on July 3, 2001 and is headquartered in Suzhou, China. | Chemicals: Specialty | Director/Board Member | |
| Nanjing Agricultural University | College/University | Doctorate Degree | |
| NANJING SINOLIFE UNITED COMPANY LIMITED | Pharmaceuticals: Other | Director/Board Member | |
Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd.
 Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. Medical SpecialtiesHealth Technology Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd. is a private company that manufactures medical equipment. The company is based in Wuxi, China. The Chinese company was founded in 1999. The CEO is Qing Song Sheng. | Medical Specialties | Director/Board Member | |
| China Pharmaceutical University | College/University | Graduate Degree | |
| Agricultural University of Hebei | College/University | Graduate Degree | |
| Nanjing University of Aeronautics & Astronautics | College/University | Masters Business Admin | |
| The University of Western Australia | College/University | Doctorate Degree | |
| University of Illinois | College/University | Graduate Degree | |
| JIANGSU HUALAN NEW PHARMACEUTICAL MATERIAL CO.,LTD. | Containers/Packaging | Director/Board Member | |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
 PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Miscellaneous Commercial Services | Director/Board Member | |
| Shanghai Jiao Tong University | College/University | Masters Business Admin | |
| Wuhan Polytechnic University | College/University | Undergraduate Degree | |
| SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Miscellaneous Commercial Services | Director/Board Member | |
Genor Biopharma Co., Ltd.
 Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Biotechnology | Director/Board Member | |
| Stanford University | College/University | Graduate Degree | |
| The Hong Kong University of Science & Technology | College/University | Undergraduate Degree | |
| Shanghai Panxin Equity Investment Management Co. Ltd. | Chief Investment Officer | ||
Citigroup Global Markets Asia Ltd.
 Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Investment Banks/Brokers | Corporate Officer/Principal | |
| ZHAOKE OPHTHALMOLOGY LIMITED | Pharmaceuticals: Major | Director/Board Member | |
| GENOR BIOPHARMA HOLDINGS LIMITED | Biotechnology | Director/Board Member | |
| Thomas Jefferson University | College/University | Doctorate Degree | |
| Auburn University | College/University | Doctorate Degree | |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Pharmaceuticals: Major | Director/Board Member | |
| PHARMABLOCK SCIENCES (NANJING), INC. | Miscellaneous Commercial Services | Chief Executive Officer | |
| NANJING MEDLANDER MEDICAL TECHNOLOGY CO.,LTD. | Medical Specialties | Director/Board Member | |
| University of Mississippi | College/University | Masters Business Admin |
Statistik
International
| China | 22 |
| Vereinigte Staaten | 7 |
| Hong Kong | 4 |
| Cayman Islands | 3 |
| Singapur | 2 |
Sektoral
| Consumer Services | 17 |
| Health Technology | 10 |
| Commercial Services | 5 |
| Process Industries | 3 |
| Electronic Technology | 2 |
Operativ
| Director/Board Member | 29 |
| Independent Dir/Board Member | 8 |
| Graduate Degree | 7 |
| Doctorate Degree | 7 |
| Corporate Officer/Principal | 5 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Yu Chen | 11 |
| Dan Liu | 6 |
| Min Min Yang | 5 |
| De Rong Leng | 4 |
| Bo Yu | 4 |
| Juan Du | 3 |
| Xing Bo Gu | 2 |
| Zhong Yu Li | 2 |
| Jing Zhao | 2 |
| Xiang Gao | 2 |
| Cun Xiang Ju | 2 |
| Tao Wen | 2 |
| Hui Xin Yang | 2 |
| Xiao Shan Jiao | 2 |
| Tao Wang | 2 |
- Börse
- Insiders
- Bin Qing Xiao
- Unternehmensverbindungen
